Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions

Clinical and Experimental Immunology

Volumn 186, Issue 3, 2016, Pages 364-372

  Vultaggio, A ^a,b   Petroni, G ^a   Pratesi, S ^a   Nencini, F ^a   Cammelli, D ^b   Milla, M ^b   Prignano, F ^c   Annese, V ^b   Romagnani, S ^a   Maggi, E ^a   Matucci, A ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

allergy; arthritis; cytokines; T cells

Indexed keywords

DRUG ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN E; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; ALLOANTIBODY; ANTIRHEUMATIC AGENT; CYTOKINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL OUTCOME; COCULTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNODETECTION; IMMUNOGENICITY; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MEMORY T LYMPHOCYTE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; AGED; BLOOD; COMPLICATION; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; ANTIRHEUMATIC AGENTS; CYTOKINES; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN E; INFLIXIMAB; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS;

EID: 84994462041     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12858     Document Type: Article

References (27)

1. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res 2015; 165:270–82.
2. Bressler B, Haraoui B, Keystone E, Sette A. Optimizing use of tumor necrosis factor inhibitors in the management of immune-mediated inflammatory diseases. J Rheumatol Suppl 2010; 85:40–52.
3. Siddiqui MA, Scott LJ. Infliximab: a review of its use in Crohn's disease and rheumatoid arthritis. Drugs 2005; 65:2179–88.
4. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:164–72.
5. Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58:1248–57.
6. Arora T, Padaki R, Liu L et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009; 45:124–31.
7. Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxf) 2010; 49:1215–8.
8. Matucci A, Pratesi S, Petroni G et al. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab. Clin Exp Allergy 2013; 43:659–64.
9. Ben-Horin S, Yavzori M, Katz L et al. The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60:41–8.
10. Delluc S, Ravot G, Maillere B. Quantitative analysis of the CD4 T-cell repertoire specific to therapeutic antibodies in healthy donors. FASEB J 2011; 25:2040–8.
11. Brown SG. Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 2004; 114:371–6.
12. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14:1660–6.
13. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1:514
14. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 2005; 23:S93–9.
15. Braun J, Pham T, Sieper J et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817–24.
16. Mukhtyar C, Lee R, Brown D et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009; 68:1827–32.
17. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008; 48:1267–81.
18. Vultaggio A, Matucci A, Nencini F et al. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65:657–61.
19. Van den Bosch F, Deodhar A. Treatment of spondyloarthritis beyond TNF-alpha blockade. Best Pract Res Clin Rheumatol 2014; 28:819–27.
20. Maggi E, Vultaggio A, Matucci A. Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 2011; 7:55–63.
21. Vultaggio A, Matucci A, Nencini F et al. Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab. Int Arch Allergy Immunol 2012; 159:321–6.
22. Evans HG, Roostalu U, Walter GJ et al. TNF-α blockade induces IL-10 expression in human CD4+ T cells. Nat Commun 2014; 5:3199.
23. Boks MA, Kager-Groenland JR, Mousset CM, van Ham SM, ten Brinke A. Inhibition of TNF receptor signaling by anti-TNFα biologicals primes naïve CD4(+) T cells towards IL-10(+) T cells with a regulatory phenotype and function. Clin Immunol 2014; 151:136–45.
24. Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011; 140:221–30.
25. Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128:376–92.
26. Baldwin HM, Ito-Ihara T, Isaacs JD, Hilkens CM. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2010; 69:1200–7.
27. Belostocki K, Pricop L, Redecha PB et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58:384–8.